IMC Chicago’s BioCryst Pharmaceuticals BCRX Stock Holding History

IMC Chicago’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Buy	+166,900	New	+$1.51M	﹤0.01%	3242

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

IMC Chicago's BCRX Position: Q2 2026 in Review

IMC Chicago increased its BioCryst Pharmaceuticals (BCRX) stake by 159% in Q2 2026, buying an estimated $9.07M and bringing the position to 1,634,336 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1200.

IMC Chicago first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

IMC Chicago held 1,634,336 shares of BioCryst Pharmaceuticals worth $16.3M as of Q2 2026.
IMC Chicago bought 1,003,046 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $9.07M.
BioCryst Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #1200 holding.
IMC Chicago first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.